vs
Side-by-side financial comparison of AETHLON MEDICAL INC (AEMD) and Netcapital Inc. (NCPL). Click either name above to swap in a different company.
Netcapital Inc. is the larger business by last-quarter revenue ($94.3K vs $60.0K, roughly 1.6× AETHLON MEDICAL INC). Netcapital Inc. runs the higher net margin — -1921.5% vs -2926.4%, a 1004.9% gap on every dollar of revenue.
Aethlon Medical Inc. is a clinical-stage medical technology firm that develops targeted therapeutic devices to address life-threatening health conditions. Its lead product, the Hemopurifier, is designed to remove harmful viruses, cancer-derived exosomes, and other pathogens from the bloodstream. The company primarily operates in the infectious disease and oncology healthcare segments, with main market presence in North America.
Netcapital Inc. runs a U.S.-focused digital private capital markets platform that connects growth-seeking early startups, small and medium private businesses with accredited and non-accredited individual investors, providing fundraising support for issuers and accessible alternative investment options for platform users.
AEMD vs NCPL — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $60.0K | $94.3K |
| Net Profit | $-1.8M | $-1.8M |
| Gross Margin | — | 98.1% |
| Operating Margin | -3026.4% | -2304.6% |
| Net Margin | -2926.4% | -1921.5% |
| Revenue YoY | — | -38.2% |
| Net Profit YoY | 49.4% | 39.7% |
| EPS (diluted) | $-10.05 | $-0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $94.3K | ||
| Q4 25 | — | $51.1K | ||
| Q3 25 | — | $190.1K | ||
| Q2 25 | — | $404.0K | ||
| Q1 25 | — | $152.7K | ||
| Q4 24 | $60.0K | $170.5K | ||
| Q3 24 | $95.1K | $142.2K | ||
| Q2 24 | — | $347.2K |
| Q1 26 | — | $-1.8M | ||
| Q4 25 | — | $-2.1M | ||
| Q3 25 | — | $-3.6M | ||
| Q2 25 | — | $-20.5M | ||
| Q1 25 | — | $-3.0M | ||
| Q4 24 | $-1.8M | $-2.2M | ||
| Q3 24 | $-2.8M | $-2.5M | ||
| Q2 24 | — | — |
| Q1 26 | — | 98.1% | ||
| Q4 25 | — | 96.3% | ||
| Q3 25 | — | 96.1% | ||
| Q2 25 | — | 99.2% | ||
| Q1 25 | — | 95.3% | ||
| Q4 24 | — | 88.4% | ||
| Q3 24 | — | 92.8% | ||
| Q2 24 | — | 96.8% |
| Q1 26 | — | -2304.6% | ||
| Q4 25 | — | -4149.6% | ||
| Q3 25 | — | -1728.8% | ||
| Q2 25 | — | -476.0% | ||
| Q1 25 | — | -1105.4% | ||
| Q4 24 | -3026.4% | -1291.5% | ||
| Q3 24 | -3050.2% | -1763.5% | ||
| Q2 24 | — | — |
| Q1 26 | — | -1921.5% | ||
| Q4 25 | — | -4169.3% | ||
| Q3 25 | — | -1916.3% | ||
| Q2 25 | — | -5085.6% | ||
| Q1 25 | — | -1969.1% | ||
| Q4 24 | -2926.4% | -1302.1% | ||
| Q3 24 | -2950.2% | -1776.9% | ||
| Q2 24 | — | — |
| Q1 26 | — | $-0.32 | ||
| Q4 25 | — | $-0.44 | ||
| Q3 25 | — | $-1.27 | ||
| Q2 25 | — | $-11.38 | ||
| Q1 25 | — | $-1.57 | ||
| Q4 24 | $-10.05 | $-2.34 | ||
| Q3 24 | $-16.11 | $-5.10 | ||
| Q2 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.8M | — |
| Total DebtLower is stronger | — | $492.4K |
| Stockholders' EquityBook value | $4.3M | $21.6M |
| Total Assets | $6.5M | $26.1M |
| Debt / EquityLower = less leverage | — | 0.02× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $4.8M | — | ||
| Q3 24 | $6.9M | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $492.4K | ||
| Q4 25 | — | $495.8K | ||
| Q3 25 | — | $500.0K | ||
| Q2 25 | — | $500.0K | ||
| Q1 25 | — | $500.0K | ||
| Q4 24 | — | $500.0K | ||
| Q3 24 | — | $500.0K | ||
| Q2 24 | — | $500.0K |
| Q1 26 | — | $21.6M | ||
| Q4 25 | — | $21.4M | ||
| Q3 25 | — | $23.1M | ||
| Q2 25 | — | $14.9M | ||
| Q1 25 | — | $35.0M | ||
| Q4 24 | $4.3M | $37.4M | ||
| Q3 24 | $6.0M | $37.5M | ||
| Q2 24 | — | $37.9M |
| Q1 26 | — | $26.1M | ||
| Q4 25 | — | $25.4M | ||
| Q3 25 | — | $28.4M | ||
| Q2 25 | — | $20.9M | ||
| Q1 25 | — | $39.9M | ||
| Q4 24 | $6.5M | $41.9M | ||
| Q3 24 | $8.8M | $41.4M | ||
| Q2 24 | — | $41.6M |
| Q1 26 | — | 0.02× | ||
| Q4 25 | — | 0.02× | ||
| Q3 25 | — | 0.02× | ||
| Q2 25 | — | 0.03× | ||
| Q1 25 | — | 0.01× | ||
| Q4 24 | — | 0.01× | ||
| Q3 24 | — | 0.01× | ||
| Q2 24 | — | 0.01× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.0M | $-868.7K |
| Free Cash FlowOCF − Capex | $-2.0M | — |
| FCF MarginFCF / Revenue | -3357.0% | — |
| Capex IntensityCapex / Revenue | 3.7% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $-868.7K | ||
| Q4 25 | — | $-2.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | — | $-5.3M | ||
| Q1 25 | — | $-1.2M | ||
| Q4 24 | $-2.0M | $-1.5M | ||
| Q3 24 | $-2.2M | $-2.0M | ||
| Q2 24 | — | $-4.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-2.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -3357.0% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 3.7% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
